期刊文献+

HPLC法测定匹多莫德中的有关物质 被引量:4

Determination of pidotimod and its related substances by HPLC
在线阅读 下载PDF
导出
摘要 目的建立测定匹多莫德有关物质的HPLC法。方法色谱柱为Welch Xtimate NH2柱(4.6 mm×250 mm,5μm),保护柱为Welch Ultimate LP-C18柱(4.6 mm×30 mm,5μm),流动相为10 mmol·L^-1磷酸二氢铵溶液(用体积分数10%磷酸调节pH值至3.0)(A)-乙腈(B),梯度洗脱,流速为1.0 mL·min^-1,柱温25℃,检测波长210 nm。结果匹多莫德质量浓度在1.51~18.1 mg·L^-1内与峰面积线性关系良好(r=0.999 8,n=6),最低检出量为3.0 ng;匹多莫德主成分与酸、碱、热、氧化、光照下的降解产物及主要降解产物之间均有良好的分离。结论本方法简便、灵敏、专属性强,适用于匹多莫德原料的质量控制。 Objective To develop an HPLC method for determination of the related substances of pidotimod. Methods A Welch Xtimate NH2 (4. 6 mm× 250 mm,5 μm)analytical column with a Welch Ultimate LP- C18(4. 6 mm× 30 mm,5 μm)guaranteed column was used for the determination, and the constitutes were separated out with gradient elution method, the mobile phase consisted of 10 mmol· L^-1 ammonium dihydro- gen phosphate solution(pH was adjusted to 3.0 by 10% phosphoric acid)( mobile phase A)and acetonitrile (mobile phase B ), and the flow rate was 1.0 mL·min^-1. The temperature of column was set at 25 ℃. UV detection was set at 210 nm. Results The calibration curve was linear in the range of 1.51- 18.1 mg·L^-1 ( r = 0. 999 8, n = 6 ). The limit of detection for the assay was 3.0 ng. Conclusions The method is simple, ac- curate and sensitive, and can be used to determine pidotimod and its related substances.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2014年第10期772-777,共6页 Journal of Shenyang Pharmaceutical University
关键词 匹多莫德 有关物质 高效液相色谱法 pidotimod related substance HPLC
作者简介 方克忠(1977-),男(汉族),山东诸城人,硕士研究生,E-maillunanjiayuan@163.com; 于治国(1958-),男(汉族),山东莱西人,教授,博士,博士生导师,主要从事中药复方药物代谢动力学及中药质量控制方法研究,Tel.024-23986295,E-mailyzg-cnn@163.com。
  • 相关文献

参考文献7

二级参考文献19

  • 1田新平,曾小峰.新型合成免疫调节剂——匹多莫德[J].中国新药杂志,2005,14(1):111-114. 被引量:97
  • 2[1]F Capsoni,F Minonzio,A Mongari, et al. Evaulation of the kinetics of the imunomodulation activity of pidotimod on human[J].Neutrophils pharmacol,Res,1992,26(Suppl 2):172.
  • 3[2]Barchielli,M,Coppi G.et al.Experimental studies on PGT/1A,a new immunostimulating drug[J].Eur J Pharmacol, 1990,183:909.
  • 4[3]P Careddu,V Mei,Venturoli,et al. Pidotimod in the treatment of recurrent respiratory infections in the paediatric patients[J].ArzneimforForsch/Drug Res, 1994,44:1 485.
  • 5[4]G Motta, E De Campora C,De Vita,et al. Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood[J].Arzneim-Forsch/Drug Res,1994,44:1 521.
  • 6[5]E Clemente,R Solli,V Mei, et al. Therapeutic efficacy and safety of pidotimod in the treatment of urinary tract infections in children[J].Arzneim-Forsch/Drug Res, 1994,44:1 490.
  • 7[6]E Pozzi, A Dolcetti, O Orlandi, et al. Pidotimod in the treatment of patients affected by bacterial exacerbations of chronic bronchiyis[J].Arzneim-Forsch/Drug Res, 1994,44:1 495.
  • 8[7]G P benetti,M IIIeni,A Passera,et al. Exvivo evaluation of pidotimod activity in patient with chronic obstructive pulmonary disease[J].Arzneim-Forsch/Drug Res, 1994,44:1 503.
  • 9安鲁凡,单世明,余书勤.匹多替莫[J].中国新药杂志,1997,6(2):110-111. 被引量:16
  • 10林冬杰.中药退黄外洗液中大黄酸的含量测定[J].中国当代医药,2009,16(4):42-43. 被引量:14

共引文献144

同被引文献23

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部